Ongoing studies
Date/ registration until
Contact persons
Blanche Pirotte +41 22 372 29 83, e-mail: evoke@hcuge.ch (Genève)
Olivier Rouaud, +41 21 314 51 51 (Lausanne)
Ansgar Felbecker, +41 71 494 16 70 (Sankt Gallen)
Aleksandra Fréville (en français), +41 32 324 44 22, e-mail: info-neurologie@szb-chb.ch (Bienne)
Sofia Schuepbach (auf Deutsch), +41 32 324 44 22, e-mail: info-neurologie@szb-chb.ch (Biel)
Drug under evaluation for early Alzheimer's disease

This international clinical trial is evaluating the efficacy and safety of a drug to determine whether it can delay the progression of symptoms associated with early Alzheimer's disease.

To be eligible to participate in this study, you must:

  • Be between 55 and 85 years old (included)
  • Have early-stage Alzheimer's disease, without being excessively restricted by memory problems in daily life
  • Have a partner or significant other who can be present during visits and provide information about the participant's health

The Evoke/Evoke+ study lasts approximately 3 years with 17 visits (1 visit approximately every 3 months) to one of the participating Memory Centres (Geneva, Lausanne, St. Gallen or Biel) and includes

  • memory tests and questionnaires
  • blood samples
  • an electrocardiogram
  • physical and neurological examinations
  • an MRI of the brain 
  • a medical examination of your choice to test for a protein involved in Alzheimer's disease (amyloid)

Participants will receive either the study drug (one of two) or a placebo daily in oral form. 

On request, the results of the various tests can be forwarded to the treating physician.

All data will be treated confidentially.

Compensation: Travel and food expenses for the participant and his/her companion

The study requires participants who meet certain criteria (see above). If you would like to participate in a study but do not meet the Evoke/Evoke+ criteria, you can register with the BHR. You will be contacted as soon as your profile matches a study.


Dernière mise à jour : 06/10/2023